ClinicalTrials.gg
CompletedNCT00282217Updated Mar 22, 2007

Study Evaluating Sirolimus in the Treatment of Kidney Transplant

A Phase 4 interventional study of Sirolimus in Kidney Failure and Kidney Diseases, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 13 sites in Spain. Per ClinicalTrials.gov, last updated 2007-03-22.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing sirolimus in Renal Insufficiency — none open to participants now, none under way, none of them phase 3. Sirolimus · Renal Insufficiency.

Enrollment
5th of 16
100 · median 63
Started
2006
with 2 others
Phase 4
6 of 16
none open now
Registered
10th of 16
by date
Lead sponsor
7 of 16
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 16 studies testing sirolimus in Renal Insufficiency, this one is the 5th largest by enrollment, is one of 3 that started in 2006, is one of 6 in phase 4, and was the 10th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 16 studies testing sirolimus in Renal Insufficiency is open now. The open studies under Renal Insufficiency, anywhere →

About sirolimus

Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing sirolimus in Renal Insufficiency as a file.
02

Study summary

The aim of this study is to test whether withdrawal of calcineurin inhibitors, followed by treatment with sirolimus, may improve renal function in renal transplant recipients with chronic allograft nephropathy.

03

Conditions studied

  • Kidney Failure
  • Kidney Diseases

Keywords

  • Kidney Failure
  • Kidney Transplant
  • Graft Rejection
  • Kidney Transplantation
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Renal transplantation
  • -confirmed chronic rejection
  • Treatment with mofetil mycophenolate among cyclosporine or tacrolimus

Exclusion criteria

Exclusion Criteria:

  • Transplant of any organ other than the kidney
  • Current important infection
  • Acute rejection within 12 weeks prior to inclusion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Renal function at 12 months; Comparison between slopes of glomerular filtration rate (GFR) of one year before versus one year after start on sirolimus

Secondary outcomes

  1. Histological parameters at 12 months

  2. Cumulative incidence of biopsy-confirmed acute rejection at 12 months

  3. Effect at 12 months on proteinuria, blood pressure, hyperlipidemia, and proteinuria

07

Study locations

13 sites
  • Albacete, 2006, Spain
  • Barcelona, 8035, Spain
  • Cadiz, 11009, Spain
  • Granada, 18014, Spain
  • L'Hospitalet de Llobregat, 8701, Spain
  • La Coruna, 15006, Spain
  • Madrid, 28034, Spain
  • Madrid, 28035, Spain
  • Madrid, 28040, Spain
  • Malaga, 29010, Spain
  • Oviedo, 33006, Spain
  • Sevilla, 41013, Spain
  • Zaragoza, 50009, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 22, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00282217
First posted
Jan 25, 2006
Start date
Aug 2006
Last update
Mar 22, 2007

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For Spain, infomed@wyeth.com
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion